ATE355375T1
(de)
|
1996-01-04 |
2006-03-15 |
Novartis Vaccines & Diagnostic |
Bakterioferritin aus helicobacter pylori
|
IL154853A0
(en)
|
2000-10-27 |
2003-10-31 |
Chiron Spa |
Nucleic acids and proteins from streptococcus groups a & b
|
US7776523B2
(en)
|
2000-12-07 |
2010-08-17 |
Novartis Vaccines And Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
JP4646516B2
(ja)
|
2002-02-20 |
2011-03-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着したポリペプチド含有分子を有する微粒子
|
EP2302039A1
(en)
|
2002-06-13 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Virus-like particles comprising HML-2 gag polypeptide
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
EP2351579B1
(en)
|
2002-10-11 |
2016-09-21 |
Novartis Vaccines and Diagnostics S.r.l. |
Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
|
EP2279746B1
(en)
|
2002-11-15 |
2013-10-02 |
Novartis Vaccines and Diagnostics S.r.l. |
Surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP2263687B1
(en)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions containing phospholipid
|
ATE552844T1
(de)
|
2003-01-30 |
2012-04-15 |
Novartis Ag |
Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
NZ543467A
(en)
|
2003-04-10 |
2008-07-31 |
Novartis Vaccines & Diagnostic |
The severe acute respiratory syndrome coronavirus
|
ES2596553T3
(es)
|
2003-06-02 |
2017-01-10 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
BR122017002991B1
(pt)
|
2003-10-02 |
2023-01-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos
|
CA2559371C
(en)
|
2004-03-09 |
2014-07-08 |
Chiron Corporation |
Influenza virus vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
WO2005105140A2
(en)
|
2004-04-30 |
2005-11-10 |
Chiron Srl |
Meningococcal conjugate vaccination
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2811027A1
(en)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for RSV and PIV vaccines
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
CN101107007B
(zh)
|
2005-01-27 |
2011-08-17 |
奥克兰儿童医院及研究中心 |
对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
ATE552267T1
(de)
|
2005-02-18 |
2012-04-15 |
Novartis Vaccines & Diagnostic |
Immungene von uropathogenen escherichia coli
|
DK1858920T3
(en)
|
2005-02-18 |
2016-02-29 |
Glaxosmithkline Biolog Sa |
PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI
|
JP5006196B2
(ja)
|
2005-08-01 |
2012-08-22 |
久光製薬株式会社 |
経皮または経粘膜投与のためのアジュバントおよび製剤
|
EP2357000A1
(en)
|
2005-10-18 |
2011-08-17 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
ES2792398T3
(es)
|
2005-11-04 |
2020-11-11 |
Seqirus Uk Ltd |
Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
EP1945253A2
(en)
*
|
2005-11-04 |
2008-07-23 |
Novartis Vaccines and Diagnostics S.r.l. |
Adminstration routes for priming/boosting with influenza vaccines
|
EP1969001A2
(en)
|
2005-11-22 |
2008-09-17 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
WO2007085969A2
(en)
|
2006-01-27 |
2007-08-02 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Influenza vaccines containing hemagglutinin and matrix proteins
|
US8535683B2
(en)
|
2006-03-22 |
2013-09-17 |
Abbott Biologicals B.V. |
Intranasal or inhalational administration of virosomes
|
EP2357184B1
(en)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
EP2004226A1
(en)
*
|
2006-03-24 |
2008-12-24 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Storage of influenza vaccines without refrigeration
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
CA2659552A1
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
US20100010199A1
(en)
|
2006-09-11 |
2010-01-14 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
WO2008068631A2
(en)
|
2006-12-06 |
2008-06-12 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
WO2008093772A1
(ja)
*
|
2007-01-31 |
2008-08-07 |
Hisamitsu Pharmaceutical Co., Inc. |
経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
|
PL2185191T3
(pl)
|
2007-06-27 |
2013-02-28 |
Novartis Ag |
Szczepionki przeciwko grypie o małej zawartości dodatków
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
WO2009076158A1
(en)
|
2007-12-07 |
2009-06-18 |
Novartis Ag |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
BRPI0821240B8
(pt)
|
2007-12-21 |
2022-10-04 |
Novartis Ag |
formas mutantes de estreptolisina o
|
EP2886551A3
(en)
|
2008-02-21 |
2015-09-23 |
Novartis AG |
Meningococcal fhbp polypeptides
|
ES2557282T3
(es)
|
2008-03-10 |
2016-01-25 |
Children's Hospital & Research Center At Oakland |
Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
|
CN102245198B
(zh)
|
2008-12-09 |
2016-08-17 |
辉瑞疫苗有限责任公司 |
IgE CH3肽疫苗
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
US8465751B2
(en)
|
2009-01-12 |
2013-06-18 |
Novartis Ag |
Cna—B domain antigens in vaccines against gram positive bacteria
|
DK2396032T3
(en)
|
2009-02-10 |
2016-12-19 |
Seqirus Uk Ltd |
Influenza vaccines with reduced amounts of squalene
|
JP2012519482A
(ja)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
クラミジア抗原
|
EP2419129A2
(en)
|
2009-04-14 |
2012-02-22 |
Novartis AG |
Compositions for immunising against staphylococcus aerus
|
CA2757620C
(en)
|
2009-04-30 |
2016-04-26 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
US9526778B2
(en)
|
2009-06-15 |
2016-12-27 |
Institut Pasteur De Lille |
Influenza vaccine, composition, and methods of use
|
EP2451833B1
(en)
|
2009-07-07 |
2018-01-17 |
GlaxoSmithKline Biologicals SA |
Conserved escherichia coli immunogens
|
AR077757A1
(es)
|
2009-07-15 |
2011-09-21 |
Novartis Ag |
Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
|
EP2464658B1
(en)
|
2009-07-16 |
2014-10-01 |
Novartis AG |
Detoxified escherichia coli immunogens
|
CA2768346A1
(en)
|
2009-07-30 |
2011-02-03 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
CA2772104A1
(en)
|
2009-08-27 |
2011-03-03 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
HUE037416T2
(hu)
|
2009-09-03 |
2018-08-28 |
Pfizer Vaccines Llc |
PCSK9 vakcina
|
ES2812523T3
(es)
|
2009-09-30 |
2021-03-17 |
Glaxosmithkline Biologicals Sa |
Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
MX2012004850A
(es)
|
2009-10-27 |
2012-05-22 |
Novartis Ag |
Polipeptidos fhbp meningococicos modificados.
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
CN102762224A
(zh)
|
2009-12-22 |
2012-10-31 |
塞尔德克斯医疗公司 |
疫苗组合物
|
JP5781542B2
(ja)
|
2009-12-30 |
2015-09-24 |
ノバルティス アーゲー |
E.coliキャリアタンパク質に結合体化した多糖免疫原
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
BR122021020829B8
(pt)
|
2010-03-30 |
2022-12-27 |
Children´S Hospital & Res Center At Oakland |
Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
CA2800774A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
EP3153578A1
(en)
|
2010-07-06 |
2017-04-12 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
EP4144368A1
(en)
|
2011-01-26 |
2023-03-08 |
GlaxoSmithKline Biologicals S.A. |
Rsv immunization regimen
|
EP2680883B1
(en)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Pcsk9 vaccine
|
ES2782119T3
(es)
|
2011-05-13 |
2020-09-10 |
Glaxosmithkline Biologicals Sa |
Antígenos de F de prefusión del VRS
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
EP2736921B1
(en)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
SG11201406592QA
(en)
|
2012-05-04 |
2014-11-27 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
CA2874210A1
(en)
|
2012-05-22 |
2013-11-28 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
EA201590427A1
(ru)
|
2012-10-02 |
2015-09-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Нелинейные сахаридные конъюгаты
|
EP2903638B1
(en)
|
2012-10-03 |
2019-12-18 |
GlaxoSmithKline Biologicals SA |
Immunogenic composition
|
AU2013351182C1
(en)
|
2012-11-30 |
2018-11-08 |
Glaxosmithkline Biologicals Sa |
Pseudomonas antigens and antigen combinations
|
CA2909586C
(en)
|
2013-05-15 |
2021-08-31 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9993549B2
(en)
|
2013-10-31 |
2018-06-12 |
Hisamitsu Pharmaceutical Co., Inc. |
Adjuvant composition, adjuvant preparation containing same, and kit
|
BR112016015525A2
(pt)
|
2014-01-21 |
2017-10-24 |
Pfizer |
composições imunogênicas compreendendo antígenos sacarídeos capsulares conjugados e uso
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3104877B1
(en)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9 vaccine and methods of using the same
|
NZ766005A
(en)
|
2014-07-23 |
2024-03-22 |
Children’S Hospital & Res Center At Oakland |
Factor h binding protein variants and methods of use thereof
|
DK3244917T3
(da)
|
2015-01-15 |
2023-05-22 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
WO2016193405A1
(en)
|
2015-06-03 |
2016-12-08 |
Affiris Ag |
Il-23-p19 vaccines
|
US20180186896A1
(en)
|
2015-07-07 |
2018-07-05 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
IL303998A
(en)
|
2015-07-21 |
2023-08-01 |
Pfizer |
Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
|
EP3377098A1
(en)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2017125844A1
(en)
|
2016-01-19 |
2017-07-27 |
Pfizer Inc. |
Cancer vaccines
|
EP3570879B1
(en)
|
2017-01-20 |
2022-03-30 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
AU2020375214B2
(en)
|
2019-11-01 |
2024-02-08 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20230085173A1
(en)
|
2020-02-21 |
2023-03-16 |
Pfizer Inc. |
Purification of saccharides
|
CN115605498A
(zh)
|
2020-02-23 |
2023-01-13 |
辉瑞公司(Us) |
大肠杆菌组合物及其方法
|
KR20230096033A
(ko)
|
2020-10-27 |
2023-06-29 |
화이자 인코포레이티드 |
에스케리키아 콜라이 조성물 및 그의 방법
|
MX2023005221A
(es)
|
2020-11-04 |
2023-05-16 |
Pfizer |
Composiciones inmunogenicas para uso en vacunas neumococicas.
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
TWI750929B
(zh)
*
|
2020-12-02 |
2021-12-21 |
林建宏 |
氣霧免疫用之溫敏型佐劑及其製作方法
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
CA3211240A1
(en)
|
2021-02-19 |
2022-08-25 |
Sanofi Pasteur Inc. |
Meningococcal b recombinant vaccine
|
WO2022234483A1
(en)
|
2021-05-04 |
2022-11-10 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
CA3221075A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2022249106A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023092090A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|